NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a Company developing targeted carbohydrate therapeutic compounds to treat cancer and fibrosis, today announced it is collaborating with BioCancell Therapeutics (TASE: BICL) to target destruction of H19 genes in cancer cells by delivering small interfering Ribonucleic Acid (siRNA) through intravenous administration of Pro-Pharmaceuticals’ DAVANAT® and BioCancell's BC-819 patient-oriented, targeted therapy. H19 genes are expressed post-natally only in cancerous cells and are believed to enable tumor cells to survive and proliferate. siRNA are a class of 20-25 nucleotide-long double-stranded RNA molecules that are involved in the RNA interference (RNAi) pathway where the siRNA interferes with the expression of a specific gene.
